Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosunetuzumab + lenalidomide
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Mosunetuzumab + lenalidomide is an investigational combination therapy being evaluated for the treatment of follicular lymphoma. Mosunetuzumab is a CD20xCD3 bispecific antibody that redirects T cells to engage and eliminate malignant B cells, while lenalidomide is a potent immunomodulatory agent that can stop cancer cells from developing and help the immune system attack cancer cells. The combination is designed to provide synergistic effects in treating lymphoma, particularly in relapsed/refractory settings.
- Other names
- M+LenMosun+LenM-Len
02
Targets
Beyond the preview
Go deeper on mosunetuzumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosunetuzumab + lenalidomide.